Phase 2 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 75 years old whose colorectal cancer has spread (metastatic) and has been confirmed by a laboratory test (biopsy)
- People whose cancer has a specific genetic profile known as microsatellite stable (MSS) or mismatch repair proficient (pMMR) (confirm with trial site if unsure what this means)
- People who have not yet received any systemic (whole-body) treatment, such as chemotherapy, for their advanced or metastatic cancer
- People who have at least one tumour that can be measured using standard imaging guidelines
- People who are generally well enough to carry out daily activities with little or no restriction (rated 0 or 1 on a standard medical scale called ECOG)
- People whose blood counts, liver, kidneys, and clotting function are within acceptable ranges
- People with a life expectancy of at least 12 weeks
- People who are willing to provide tumour tissue samples for research testing
- People who are able to give written consent to participate in the trial
Who may not be able to join:
- People who have previously been treated with certain targeted therapies known as EGFR- or HER3-targeted antibody-drug conjugates, or similar drugs that work via a mechanism called topoisomerase I inhibition
- People who have recently had major surgery, radiation therapy, or other cancer treatments close to the time of joining the trial
- People with active or uncontrolled infections, or significant heart or blood vessel disease
- People with known active cancer spread to the brain or spinal cord (central nervous system metastases)
- People with a history of autoimmune disease that has required ongoing systemic medical treatment
- People with significant bleeding disorders or a high risk of serious bleeding
- People with active, uncontrolled viral infections such as hepatitis B, hepatitis C, or HIV
- People with any other serious medical or mental health condition that could interfere with taking part in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhenyu Xu, Doctor, Medical Director
Phone: 86 18616904609
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Investigator-assessed objective response rate (ORR); Safety and Tolerability(AEs); Safety and Tolerability(SAEs); Safety and Tolerability(DLTs); Maximum Tolerated Dose (MTD); Recommended Phase 3 Dose (RP3D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.